Xevoben

Description

Xevoben, 50 mg + 12,5 mg, tablets

Xevoben, 100 mg + 25 mg, tablets

Xevoben, 200 mg + 50 mg, tablets

Xevoben XR, 100 mg + 25 mg, modified release capsules, hard

Available in packs of 100 tablets or modified release capsules.

Active ingredient:  Levodopum + Benserazidum

Indications: 

Xevoben, 50 mg + 12,5 mg, tablets is used:

• in the treatment of Parkinson’s disease (shaking palsy, a disease characterised by coarse tremors, slowed movements and muscular rigidity);
• in the treatment of symptoms that resemble those of Parkinson’s disease, but are the result of intoxication, encephalitis and brain alterations due to arteriosclerosis (symptomatic parkinsonian syndromes). Exceptions are Parkinson’s-like symptoms triggered by certain medicines (drug-induced parkinsonian syndrome).

 

Xevoben, 100 mg + 25 mg, tablets is used:

• in the treatment of Parkinson’s disease (shaking palsy, a disease characterised by coarse tremors, slowed movements and muscular rigidity);
• in the treatment of symptoms that resemble those of Parkinson’s disease, but are the result of intoxication, encephalitis and brain alterations due to arteriosclerosis (symptomatic parkinsonian syndromes). Exceptions are Parkinson’s-like symptoms triggered by certain medicines (drug-induced parkinsonian syndrome).
• in the treatment restless legs syndrome of unknown cause;
• in the treatment restless legs syndrome as a result of impaired kidney function requiring dialysis.

 

Xevoben XR, 100 mg + 25 mg, modified release capsules, hard is used:

• in the treatment of Parkinson’s disease (shaking palsy, a disease characterised by coarse tremors, slowed movements and muscular rigidity), if you already receive levodopa in combination with benserazide or carbidopa in an immediate-release dosage form;
• in the treatment of restless legs syndrome of unknown cause if you already receive levodopa in combination with benserazide or carbidopa in an immediate-release dosage form;
• in the treatment of restless legs syndrome as a result of impaired kidney function requiring dialysis if you already receive levodopa in combination with benserazide or carbidopa in an immediate-release dosage form.